Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications

医学 双盲 去神经支配 导管 随机对照试验 盲法研究 麻醉 泌尿科 外科 内科学 病理 安慰剂 替代医学
作者
Felix Mahfoud,Michael A. Weber,Roland E. Schmieder,Melvin D. Lobo,Peter J. Blankestijn,Alexandre Persu,Tim A. Fischell,Helen Parise,Atul Pathak,David E. Kandzari
出处
期刊:American Heart Journal [Elsevier]
卷期号:239: 90-99 被引量:16
标识
DOI:10.1016/j.ahj.2021.05.015
摘要

Arterial hypertension is a common and life-threatening condition and poses a large global health burden. Device-based treatments have been developed as adjunctive or alternative therapy, to be used with or without antihypertensive medication for treating uncontrolled hypertension. The safety and feasibility of chemical renal denervation (RDN) using the Peregrine Catheter and alcohol were demonstrated in a first-in-man and open-label clinical trials, prompting the initiation of the ongoing TARGET BP OFF-MED and TARGET BP I trials. The TARGET BP trials are randomized, blinded, sham-controlled trials designed to assess the safety and efficacy of alcohol-mediated RDN for the treatment of uncontrolled hypertension in the absence of antihypertensive medications (TARGET BP OFF-MED) or in addition to prescribed antihypertensive medications (TARGET BP I). Subjects with confirmed uncontrolled hypertension and suitable renal artery anatomy are randomized (1:1) to receive either RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery) infused through the Peregrine Catheter or diagnostic renal angiography only (sham procedure). TARGET BP OFF-MED completed enrollment and randomized 96 subjects. TARGET BP I will randomize approximately 300 subjects and will transition to an open-label safety cohort of approximately 300 subjects receiving RDN once the primary efficacy endpoint of the Randomized Controlled Trial (RCT) cohort has been met. Primary endpoints are change in mean 24-hour ambulatory systolic blood pressure from baseline to 8 weeks (TARGET BP OFF-MED) and 3 months (TARGET BP I) post-procedure. The TARGET BP trials are the first large-scale, international, randomized trials aimed to investigate the safety and BP lowering efficacy of a novel RDN method, with perivascular alcohol delivery using the Peregrine Kit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
孤独的狗发布了新的文献求助10
1秒前
火星上的雪曼完成签到,获得积分10
1秒前
2秒前
2秒前
Hollen完成签到 ,获得积分10
5秒前
7秒前
huanglm发布了新的文献求助10
9秒前
细心的老头完成签到 ,获得积分10
11秒前
11秒前
Wst发布了新的文献求助20
12秒前
12秒前
14秒前
韦老虎发布了新的文献求助10
14秒前
酷波er应助小乔采纳,获得10
15秒前
15秒前
研友_VZG7GZ应助佟莫言采纳,获得10
16秒前
paulmichael完成签到,获得积分10
16秒前
慧慧发布了新的文献求助10
17秒前
充电宝应助研友_VZGvVn采纳,获得10
18秒前
18秒前
wjh完成签到,获得积分10
18秒前
翟晨莹发布了新的文献求助10
18秒前
勤奋幻天完成签到 ,获得积分10
19秒前
Lucas应助儒雅的善愁采纳,获得10
20秒前
红莲墨生发布了新的文献求助10
20秒前
24秒前
ding应助精则养神采纳,获得10
25秒前
靓丽的发箍完成签到,获得积分10
25秒前
红莲墨生完成签到,获得积分10
26秒前
26秒前
27秒前
小乔发布了新的文献求助10
30秒前
30秒前
momo关注了科研通微信公众号
30秒前
WDS发布了新的文献求助30
30秒前
翟晨莹完成签到,获得积分20
32秒前
32秒前
34秒前
34秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 800
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Wisdom, Gods and Literature Studies in Assyriology in Honour of W. G. Lambert 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2389825
求助须知:如何正确求助?哪些是违规求助? 2095899
关于积分的说明 5279304
捐赠科研通 1823006
什么是DOI,文献DOI怎么找? 909413
版权声明 559621
科研通“疑难数据库(出版商)”最低求助积分说明 485949